[2] Glorius completed his Doctorate in 2000 investigating "New chiral bis-oxazoline ligands for enantioselective catalysis" at the University of Basel with Andreas Pfaltz.
Between 2000 and 2001 Glorius completed a Postdoc at Harvard University in Cambridge, with David A. Evans exploring the Total synthesis of Aflastatin A.
His research group explores a wide range of topics including the development and application of N-heterocyclic carbenes (NHCs) in catalysis,[3] exploration and use of NHCs as surface modifyers, C-H activation,[4] asymmetric organocatalysis,[5] chemo- and enantioselective hydrogenation of aromatic compounds,[6] photoredox catalysis and energy transfer photocatalysis,[7] heterogeneous catalysis, Metal Organic Frameworks/MOFs, development and use of lipid analogs, and the development of reaction screening technologies.
[8] Former members of the group have gone on to have careers in both academia (e.g. Canada, China, France, Germany, India and Japan) and industry (BASF, Bayer, Evonik, Clariant, Axalta, Lanxess, Continental, Archimica, Mitsubishi, Novartis or Janssen Pharmaceutica (Johnson & Johnson) for instance).
In 2013, he was elected as an honorary member of the Israel Chemical Society, and was named as "Highly Cited Researcher" in all the years since 2014 (currently till 2022).